To include your compound in the COVID-19 Resource Center, submit it here.

J&J reports 56-week data for Tremfya in psoriatic arthritis

The Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ) reported additional data from a Phase II trial of Tremfya guselkumab (CNTO 1959)showing that the drug maintained efficacy through 56 weeks in patients with active psoriatic arthritis.

In the 149-patient trial, 74% of patients who received 100 mg subcutaneous Tremfya at weeks 0 and 4

Read the full 561 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers